GenoMed Announces 3rd Year of its West Nile Virus Trial; Now Part of BioShield II
Contact: Paula Hempen, PhD GenoMed, Inc. tel. 314-983-9933
David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com
ST. LOUIS--June 7, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it will be conducting a clinical trial to prevent and treat West Nile virus encephalitis for the third summer in a row. The Company's approach to viral diseases was recently included in BioShield II, the landmark anti-bioterrorism bill recently introduced in the U.S. Senate by Senators Joseph Lieberman (D-CT), Orrin Hatch (R-UT), and Sam Brownback (R-KS).
A part of the bill reads:
"CHAPTER 5; REPORT AND ADMINISTRATION. SEC. 2151. REPORT TO CONGRESS. Not later than 180 days after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention, in consultation with the Assistant Secretary for Medical Readiness and Response of the Department of Homeland Security and the Director of the National Institute for Allergy and Infectious Disease of the National Institutes of Health, shall submit a report to Congress that describes alternatives to traditional vaccines and anti-viral therapeutics for viral diseases, including negative immunomodulation compounds that partially suppress a macrophage-dependent innate immune response of an individual to viral pathogens, in order to decrease morbidity and mortality from an excessive immune response."
This language exactly describes GenoMed's patent-pending method to gently suppress the innate immune response in order to treat most viral diseases in the general population.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our record in West Nile virus currently stands at 11-3. For best results, we know to use our treatment in patients who aren't immunocompromised, and to begin treatment early."
Physicians in Utah, and Stanislaus County in California, are currently studying GenoMed's WNV protocol for use in their residents.
GenoMed's protocol was also used last summer by bird rescuers, with a 50% success rate. A second trial is planned again for this summer. Owls, hawks, and eagles have been saved using GenoMed's protocol, but so far no crows. This year's goal is to try to save crows, too.
"Horses should also benefit from our approach," Dr. Moskowitz added. "Veterinarians already use non-steroidal drugs to try to reduce the brain inflammation in horses, so our anti-inflammatory approach should make sense to them."
To enroll in GenoMed's trial, which uses already existing, safe medication present in every drug store, just go to www.genomed.com and click on the link for the West Nile virus trial.
About GenoMed
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
|
